Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
35.3 CHF | +0.86% | +10.31% | -29.26% |
Apr. 23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
Feb. 29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.26% | 222M | - | ||
+23.37% | 47.02B | B- | ||
+50.30% | 41.86B | A | ||
-0.94% | 41.76B | B | ||
-4.32% | 28.8B | C | ||
+11.29% | 26.05B | B- | ||
-20.92% | 19.15B | B | ||
+3.20% | 12.55B | B+ | ||
-2.67% | 11.82B | C+ | ||
+30.23% | 12.34B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- XLS Stock
- Ratings Xlife Sciences AG